Department of Neurology, Henry Ford Hospital, Detroit, Michigan, United States of America.
PLoS One. 2013;8(1):e54083. doi: 10.1371/journal.pone.0054083. Epub 2013 Jan 14.
Human umbilical tissue-derived cells (hUTC) are a promising source of cells for regenerative treatment of stroke. In this study, we tested the efficacy of hUTC in experimental stroke and whether multiple injections of hUTC provide additional therapeutic benefits as compared to a single injection.
Adult male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAo), and randomly selected animals were injected (i.v) with 3×10⁶ hUTC or with vehicle control (at day: 1, 1&3 or 1&7 after MCAo, n = 8-9/group). A battery of functional outcome tests was performed at days 1, 7, 14, 21, 28, 35, 42, 49, 56 and 63 after MCAo. Rats were sacrificed at 63 days after MCAo and lesion volumes were measured. To investigate the underlying mechanism of hUTC treatment of stroke, Von Willebrand Factor (vWF), and Synaptophysin immunostaining were performed.
All hUTC treated groups, single or multiple injections, had better functional recovery compared to control (p<0.01). There was no statistically significant difference between a single and multiple injections of hUTC (p = 0.23) or between different multiple injections groups (p>0.07) in functional outcome. All hUTC treatment groups showed significant increases in Synaptophysin, vascular density and perimeter compared to the control group (p<0.05). There was no statistically significant difference between a single and multiple injections of hUTC or between the two groups of multiple injections in all immunohistochemical measurements (p>0.1).
hUTC treatment significantly improves long term functional outcome after stroke and promotes vascular density and synaptic plasticity. At the proscribed doses, multiple injections of hUTC were not superior to single injection therapy in both functional outcome and histological assessments.
人脐带组织来源的细胞(hUTC)是一种很有前途的细胞来源,可用于治疗中风的再生治疗。在这项研究中,我们测试了 hUTC 在实验性中风中的疗效,以及与单次注射相比,多次注射 hUTC 是否会提供额外的治疗益处。
成年雄性 Wistar 大鼠接受 2 小时大脑中动脉闭塞(MCAo),随机选择的动物接受 3×10⁶ hUTC 或载体对照(MCAo 后第 1、1&3 或 1&7 天,n = 8-9/组)静脉注射。在 MCAo 后第 1、7、14、21、28、35、42、49、56 和 63 天进行一系列功能预后测试。MCAo 后 63 天处死大鼠,测量病灶体积。为了研究 hUTC 治疗中风的潜在机制,进行了 Von Willebrand 因子(vWF)和突触素免疫染色。
与对照组相比(p<0.01),所有 hUTC 治疗组(单次或多次注射)的功能恢复都更好。单次和多次注射 hUTC 之间(p = 0.23)或不同多次注射组之间(p>0.07)在功能结果方面没有统计学上的显著差异。与对照组相比,所有 hUTC 治疗组的突触素、血管密度和周长均显著增加(p<0.05)。单次和多次注射 hUTC 之间或两组多次注射之间在所有免疫组织化学测量中均无统计学差异(p>0.1)。
hUTC 治疗可显著改善中风后的长期功能预后,并促进血管密度和突触可塑性。在所规定的剂量下,多次注射 hUTC 在功能和组织学评估方面并不优于单次注射治疗。